4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1,300.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,820.00
  • 52 Week Low: 545.00
  • Currency: UK Pounds
  • Shares Issued: 15.48m
  • Volume: 2
  • Market Cap: £201.21m
  • Beta: 0.18

Latest ShareCast News

4basebio losses widen as it progresses commercial development

By Josh White

Date: Friday 27 Sep 2024

(Sharecast News) - 4basebio, a biotechnology company specialising in synthetic DNA products and nucleic acid delivery platforms, reported revenue of over £0.3m for the six months ended 30 June on Friday.

4basebio to provide synthetic DNA to tier-one pharma firm

By Josh White

Date: Wednesday 10 Apr 2024

(Sharecast News) - 4basebio confirmed the provision of its synthetic DNA to an unnamed tier-one pharmaceutical company on Wednesday.

4basebio client gets approval to start trial in Australia

By Josh White

Date: Thursday 21 Mar 2024

(Sharecast News) - Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.

4basebio inks significant DNA supply contract 01-Mar-2024 ShareCast
First-half losses narrow for 4basebio 21-Sep-2023 ShareCast
4basebio inks supply deal with Italy's Neomatrix 25-May-2023 ShareCast
4basebio enters neurofibromatosis collaboration ... 10-Jun-2022 ShareCast
Losses to continue as 4basebio focuses on commer... 09-May-2022 ShareCast
4basebio inks development deal with Heqet Therap... 27-Apr-2022 ShareCast
4basebio launches two new synthetic DNA products 23-Mar-2022 ShareCast
4basebio makes progress with manufacturing devel... 15-Feb-2022 ShareCast
4basebio enters research collaboration with eThe... 18-Jan-2022 ShareCast
4basebio enters development deal with T-cell the... 23-Nov-2021 ShareCast
4basebio files for patent on novel DNA type 22-Jun-2021 ShareCast
 
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,300.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,820.00
52 Week Low 545.00
Volume 2
Shares Issued 15.48m
Market Cap £201.21m
Beta 0.18

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
25.57% below the market average25.57% below the market average25.57% below the market average25.57% below the market average25.57% below the market average
28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average
Price Trend
70.60% above the market average70.60% above the market average70.60% above the market average70.60% above the market average70.60% above the market average
95.92% above the sector average95.92% above the sector average95.92% above the sector average95.92% above the sector average95.92% above the sector average
Income Not Available
Growth
35.67% above the market average35.67% above the market average35.67% above the market average35.67% above the market average35.67% above the market average
35.29% above the sector average35.29% above the sector average35.29% above the sector average35.29% above the sector average35.29% above the sector average

4basebio Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:04 2 @ 1,310.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page